Get 250+ investors tailored to your startup

Invest in your industry and stage
Emails & contact info included
Excel and CSV export
Automatically

Trusted by 3,000+ startups

Top 50 Biotechnology VC (Venture Capital) Funds in Europe in December 2024

Last updated: Dec 2024 A list of 50 VC (Venture Capital) funds that invest in Biotechnology startups based in Europe. We rank investors based on the number of investments they made in Biotechnology companies from Europe. We update this investor list every month.

Top 50 Biotechnology VC (Venture Capital) Funds in Europe in December 2024

Investor	Biotechnology Europe investments
SOSV	77
Sofinnova Partners	61
UK Innovation & Science Seed Fund	57
Bpifrance	54
HTGF \| High-Tech Gruenderfonds	45
Novo Holdings	45
Parkwalk Advisors	43
Oxford Science Enterprises	38
Scottish Enterprise	38
Oxford Technology Management	35
Kurma Partners	33
Enterprise Ireland	31
Catapult Ventures	31
Scottish Investment Bank	31
Seventure Partners	30
Boehringer Ingelheim Venture Fund	29
Oxford Capital	29
GO CAPITAL	26
Mercia Fund Managers	26
Oxford Science Enterprises	26
Karista	25
BioInnovation Institute	25
M Ventures	24
Epidarex Capital	24
Centre for the Development of Industrial Technology (CDTI)	23
Development Bank of Wales	22
MIG Capital	22
Auriga Partners	22
Future Planet Capital	21
Archangels	20
Omnes Capital	20
Idinvest Partners	20
Newable Private Investing	20
AlbionVC	20
O2h Ventures	19
Deepbridge Capital	19
Criteria Venture Tech	19
Elaia	19
GM&C Life Sciences Fund	19
Meusinvest (Noshaq)	18
HealthCap	18
IP Group	18
Forbion Capital Partners	18
Cambridge Angels group	17
Kelvin Capital	17
Octopus Ventures	17
Ysios Capital	16
Syncona Partners LLP	16
Northstar Ventures	16
Wellcome Trust	16

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.

Investment focus

Biotechnology, Health Care, Software
Seed, Convertible Note, Pre-Seed
United States, India, United Kingdom

Portfolio highlights

MixRift — MIXRIFT - game developers specialized in Mixed Reality
unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
France, United States, United Kingdom

Portfolio highlights

deepc — The Radiology AI Platform - Your effortless access to AI
Genespire — Genespire is a biotechnology company focused on the development of transformative gene therapies for patients affected by genetic diseases, particularly primary immunodeficiencies and inherited metabolic diseases.
Micropep Technologies — Micropep Technologies developes a non-GMO new generation of bioherbicides and biostimulants. Micropep, founded in 2016 in Toulouse, focuses on bioherbicides and biostimulants. The company uses plants’ natural molecules, called “micro-peptides”, to temporarily control expression of their genes and regulate plant growth but leaving their DNA intact.The company currently works on four development programs: germination, flowering, growth, and weed control.

UKI2S, formally the Rainbow Seed Fund, is an investment fund backed by the government, providing seed funding to science & technology start-ups and SMEs

Investment focus

Biotechnology, Health Care, Medical
Seed, Funding Round, Series A
United Kingdom, United States

Portfolio highlights

Ikarovec — Ikarovec is developing novel gene therapies to treat major ophthalmic indications.
Antiverse — Designing biologics for 100 challenging targets
iFast Diagnostics — iFAST is addressing the Antimicrobial Susceptibility Testing market, reducing the spread of antimicrobial resistance.

Bpifrance provides financial solutions for companies that are booting up the listing on the stock exchange and credit equity. It includes OSEO, CDC Entreprises, FSI, and FSI Regions to offer in your area of financial solutions at every stage of the life of your business.Bpifrance was founded in 2012 and is based in Maisons-alfort, Ile-de-France,France.

Investment focus

Software, Information Technology, Health Care
Funding Round, Seed, Series A
France, United States, Switzerland

Portfolio highlights

Dfns — Supercharge your platform with keyless custody as a service. One API to generate secure wallets, manage your crypto, sign transactions, set up business rules, monitor security, and more.
Biolevate — Accelerating Therapeutic Innovation: AI-Enhanced Workflow Automation
Orakl Oncology — Cultivated with love by the Orakl team.

The seed investor High-Tech Gründerfonds (HTGF) finances tech start-ups with growth potential and has supported more than 700 start-ups since 2005. With the launch of its fourth fund, HTGF now has about 1.4 billion euros under management. Its team of experienced investment managers and start-up experts support young companies with expertise,entrepreneurial spirit and passion. HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial tech, life sciences, chemistry and related business areas. To date, external investors have injected about 5 billion euros of capital into the HTGF portfolio via more than 2,000 follow-on financing rounds. In addition, HTGF has already successfully sold shares in more than 170 companies. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries.

Investment focus

Software, Information Technology, Biotechnology
Seed, Series A, Funding Round
Germany, Switzerland, United States

Portfolio highlights

IonKraft — IonKraft can provide better performance at a lower cost while maintaining recyclability, they also promote material reduction and reuse and are commercializing the technology with funding from the German Federal Ministry for Economic Affairs and Energy (BMWi).
Sedivention — Sedivention is a medical technology startup that enables a one-time, interventional, and minimally invasive therapy for obesity. The company is developing a cryo catheter that ablates the gastric branches of the vagus nerve within minutes. As a one-time, minimally invasive procedure, the procedure can be performed in an outpatient setting, similarto a gastroscopy.
SRTD Biotech — SRTD Biotech is an RNA-based biotechnology company that focuses on oncology, infectious, and genetic disorders.

Novo Holdings is a world-leading life science investor with a focus on creating long-term value.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Series A, Series B, Series C
United States, Denmark, United Kingdom

Portfolio highlights

ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
Antag Therapeutics — Antag Therapeutics operator of a biotechnology company intended to develop metabolic and anti-obesity therapeutic drugs.The company specializes in the development of peptide-based GIP receptor antagonist in order to monitor dietary-related metabolic diseases through the infusion, enabling the healthcare industry to decrease blood flow and lipiduptake in adipose tissue in an efficient manner.
Nuvig Therapeutics — Nuvig Therapeutics is advancing innovative and transformational therapies that are designed to induce natural mechanisms to restore immune homeostasis, rebalance immune function following inﬂammation, and improve the treatment options for patients. Nuvig is building a pipeline of novel immune therapeutics for chronic inflammatory and autoimmunediseases.

Parkwalk is a London-based fund management firm. Parkwalk invests in UK technology companies that have IP backing and freedom to operate, generally spun out of UK universities. Their funds seek to generate capital gains for their investors, enhanced by the attractive tax relief provided by EIS. Parkwalk entered this investment sector in 2009,anticipating a wave of tax-efficient incentives launched by the UK Government to stimulate innovative emerging technology companies and thereby help drive economic growth.Parkwalk utilises academic, technology transfer, venture capital and personal networks developed over many years to gain access to the highest calibre deal-flow. In 2017 Parkwalk joined forces with IP Group plc, a leading intellectual property commercialisation company that is listed on the Main Market of the London Stock Exchange under the ticker symbol IPO. As at March 2019 the combined group has net assets of £1.2bn.

Investment focus

Biotechnology, Health Care, Software
Seed, Series A, Series B
United Kingdom, United States, Philippines

Portfolio highlights

Diffblue — Diffblue Cover uses next generation autonomous AI to automate unit testing so that Java development teams can build better applications faster
Evoralis — Utilise Our Innovative Enzymes to Efficiently Recycle Plastics Into High-Quality Raw Materials
Ikarovec — Ikarovec is developing novel gene therapies to treat major ophthalmic indications.

Oxford Science Enterprises is the university-partnered venture firm. We work with the University of Oxford to build companies that create fundamental technologies: science-based businesses capable of tackling the planet’s toughest problems. We invest in life science, AI and software, healthcare, and deep tech to create companies taking onchallenges like nuclear fusion, quantum computing and developing treatments and cures for infectious diseases. Founded in 2015, we’ve raised over £600M to create a world-class technology ecosystem, and combine our deep experience with a network of investors, entrepreneurs and sector-experts to find co-investment, build businesses, and hire senior management talent.

Investment focus

Health Care, Biotechnology, Software
Seed, Series A, Series B
United Kingdom, United States, Finland

Portfolio highlights

natcap — We support the world's leading companies to prioritise, measure and act on nature impacts, dependencies, risks and opportunities.
FluoRok — By employing our patented technology, we can produce fluorochemicals without the production of toxic and highly dangerous hydrofluoric acid
Iota Sciences — Discover automated single-cell handling tools and related services to accelerate your route to breakthrough discoveries in cell biology

Scotland's business advice, support and funding agency. Explore our products and services to find the right support for your business and apply online today.

Investment focus

Biotechnology, Software, Health Care
Grant, Funding Round, Seed
United Kingdom, United States, Japan

Portfolio highlights

MiAlgae — MiAlgae is a new-age microalgal production company that aims to revolutionize the £340 billion global livestock feed industry by producing microalgal products – through the remediation of wastewater – as nutrient supplements for fishmeal in livestock feeds. Their microalgal products are high in omegas and proteins, both of which are required forthe production of many livestock feeds, especially in the aquaculture sector.Their production methodology uses circular economy to reduce the operating costs involved in the production of microalgae and as such allows them to compete with other supplements currently on the market.
Biotangents — Biotangents develops veterinary diagnostic tests to detect infectious diseases in livestock (bovine viral diarrhoea (BVD), mastitis, bovine respiratory disease (BRD), brucellosis) using our highly adaptable molecular diagnostic technology, Moduleic Sensing.
Solasta Bio — Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection.

Oxford Technology's SEIS fund and EIS fund enable private investors to access high growth technology startup opportunities and support UK innovation. SEIS and EIS tax reliefs offer downside protection, whilst gains can be tax free.

Investment focus

Biotechnology, Health Care, Software
Seed, Funding Round, Series A
United Kingdom, United States

Portfolio highlights

OxCan — Enabling curative cancer treatment through early detection
CryoLogyx — Assay Ready Cells - Discover CryoLogyx's advanced cryopreservation solutions, optimized for cell-based assays in drug discovery. Simply thaw with cell culture medium, and they are ready for use within 24 hours post-thaw.
Metacarpal — Metacarpal design upper-limb prosthetics without compromise. We aim to make the most robust, functional hand prosthesis that people love wearing because it works so effectively and looks so beautiful. Be proud to show your artificial side!

Kurma Partners is a management company based in Paris, specializing in the financing of innovation in healthcare and biotechnology, from pre-creation to development capital. Kurma Partners, which manages the Kurma Biofund I, II funds and the Kurma Diagnostics fund, is one of the main players in the financing of therapeutic and medical innovationsin Europe, particularly through links with many institutes. research and prestigious hospitals.

Investment focus

Health Care, Biotechnology, Pharmaceutical
Series A, Series B, Seed
France, Switzerland, Spain

Portfolio highlights

Omnidoc — Omnidoc is a tele-expertise platform for healthcare professionals to exchange medical opinions.
Raidium — Radiology augmented GPT to tackle the complexity of precision medicine
PanTera — PanTera wants to bring a new hope to cancer patients by enabling the widespread use of radiopharmaceuticals for personalised treatment of tumors

Enterprise Ireland is the government agency responsible for the development and funding of the indigenous business sector. Their mission is to accelerate the development of companies to achieve strong positions in global markets resulting in increased national and regional prosperity. It was founded in 1998 and headquartered in Dublin, Ireland.

Investment focus

Software, Health Care, Information Technology
Funding Round, Seed, Series A
Ireland, United States, United Kingdom

Portfolio highlights

Ovagen — Ovagen is a biotechnology company that has developed the process of producing germ free (GF) chicken eggs and GF birds in commercial quantities for use primarily in the pharmaceutical industry. Ovagen can also provide a Contract Research Service and has extensive expertise in SPF poultry & rodent housing & husbandry, in specific poultry& rodent research technologies to GMP standards and in avian transgenics.
Customs Window — Customs Window is an End-to-End Customs Clearance and Trade Solutions providing Support Services to solve challenges and operations.
The Freebird Club — The social travel club for over 50s. Homestays, local events, travel advice and more.

The team behind Catapult Ventures are among the most experienced venture capital investors in the UK.Their experience spans a range of sectors from healthcare and pharmaceuticals to luxury consumer brands, manufacturing and software, as well as all stages: from start-ups and pre-revenue IP developers to company floatation and billions of poundsin revenue. Their administration team is equally experienced with each member having more than 10 years experience in a venture capital environment.

Investment focus

Health Care, Biotechnology, Medical
Funding Round, Seed, Series A
United Kingdom, United States, Israel

Portfolio highlights

Path Robotics — We create manufacturing robots that autonomously scan, position, and weld your parts without the need for skilled welders or robot programmers.
Pickle Robot — We make robots that unload trucks without retrofitting the warehouse
Anello Photonics — Anello Photonics is founded by pioneers in silicon photonics and inertial navigation. The patented Anello SiPhOG gyroscope offers an affordable mass-market sensor with true Optical Gyroscope performance. The company is headquartered in Silicon Valley and funded by leading venture capital firms.

Speak with our Entrepreneurship and Investment teams, who can help you find sources of finance, engage with funders and secure investment to grow your business.

Investment focus

Software, Biotechnology, Health Care
Funding Round, Seed, Series A
United Kingdom, United States, France

Portfolio highlights

Bio-Images Drug Delivery — BDD Pharma combine drug delivery expertise and clinical capabilities to accelerate product development pipelines, enable life cycle management and new innovative pharmaceutical products. Rapid parallel clinical testing with SWIFT significantly reduces time from product concept to clinical success.
IOTech — Discover IOTech Systems, the open edge data platform for developing, deploying, and managing Industrial Edge applications at scale. Find out more here.
Administrate — Manage 100% of enterprise training operations with configurable training management software, designed to scale with your organization.

Seventure Partners is a French venture capital firm targeting in information and communication technology, and life sciences companies. It funds innovation and participates in the entrepreneurial adventure, alongside entrepreneurs and sharing their passion.Founded in 1997, Seventure Partners is one of the European leaders in venture capital, with€ 660 million under management as of December 31, 2016. It is an active partner of innovative companies that, according to the management team, show strong growth potential and evolving in two fields of activity: Digital Technologies and Life Sciences. With more than 20 employees, including some 15 investors, Seventure Partners has a proven track record and in-depth expertise in technology, entrepreneurship, and various private equity operations.Seventure's goal is to identify and support the development of tomorrow's European leaders in order to accelerate their growth. To do this, the firm provides entrepreneurs with the expertise, networks, and know-how of its internal team of investors.

Investment focus

Biotechnology, Health Care, Software
Series A, Series B, Funding Round
France, United States, Germany

Portfolio highlights

Otoqi — Otoqi is a vehicle delivery platform that develops connected services and logistics solutions for the automotive professionals.
Siit — Siit is a modern IT service management platform. Conversational, integrated and AI-powered service desk for IT and internal operation teams. Simplify internal operations today!
Sequentia Biotech — Sequentia Biotech is a bioinformatics company that offers services for healthcare, pharma, agriculture, industry and environment.

The Boehringer Ingelheim Venture Fund is the strategic venture fund of the Boehringer Ingelheim Corporation.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, Germany, Belgium

Portfolio highlights

Aignostics — Aignostics is an AI-powered precision diagnostics focused on pathology to assist with drug development and clinical research. Its “explainable” AI overcomes the “black-box” limitations of conventional AI. Based on their patented technology for reverse-engineering the black box, they render diagnostic results explainable in the form of preciseheatmaps and image overlays. These heatmaps allow pathologists to quickly verify the results of the AI, which is crucial, as the pathologist is ultimately responsible for the diagnosis.The company was founded in 2018 and is headquartered in Berlin, Germany.
Glox Therapeutics — Developing novel precision antibiotics based on protein bacteriocins, to target Gram-negative Antimicrobial Resistant (AMR) pathogens.
Asgard Therapeutics — Asgard Therapeutics is a private biotech company exploring the application of direct cell reprogramming technologies for cancer immunotherapies. Formed as a spin-off from Lund University, the Company is pioneering a gene therapy approach based on its proprietary TrojanDC technology, designed to set in motion immune responses based on the biologicalproperties of professional antigen-presenting cells.

Helping individuals and institutions invest in Venture Capital, Infrastructure and Media companies since 1999.

Investment focus

Software, Health Care, Biotechnology
Funding Round, Seed, Series A
United Kingdom, United States, France

Portfolio highlights

Ittybit — Ittybit is a API that enables users to handle rich media in applications. It provides developers with basic techniques for uploading, storing, transforming, and extracting data from video, music, and image files.
HealthKey — HealthKey is a platform that connects employers and insurers with health providers.
Noggin HQ — The next generation of credit referencing is coming. Look busy.

GO CAPITAL is a management company approved by the AMF and a member of AFIC. It is based in Rennes, and manages more than 130 million of assets by investing primarily in western France in innovative companies with high growth potential.

Investment focus

Biotechnology, Software, Health Care
Funding Round, Seed, Series A
France, Canada, Israel

Portfolio highlights

BIOPHTA — BIOPHTA has pioneered a new approach to eye care by creating a cutting-edge pharmaceutical platform that enables continuous drug delivery. Their non-invasive topical ocular inserts represent a significant advancement in the treatment of many ophthalmic disorders, providing superior long-term disease management.
Brightflow — Brightflow operates as a medical device startup.
Dealt — Dealt - La solution servicielle qui transforme votre activité retail et e-commerce Montage, installation, configuration, entretien ou réparation… Dealt construit, implémente et gère votre offre de services en marque blanche, pour vous permettre de mieux accompagner vos clients et vous démarquer de la concurrence.Pour cela, Dealt met àdisposition des distributeurs une solution omnicanale complète, comprenant : - Les outils technologiques pour implémenter leur offre de services en marque blanche : plateforme de services, API, solution vendeur et back-office - Un catalogue de +300 services à tarifs négociés - Une communauté nationale de 10 000 professionnels certifiés - Un accompagnement total pour développer leur stratégie serviciellePassez d’un modèle de vendeur de produits à vendeur de solutions avec Dealt !Pourquoi adopter Dealt ? * +300 services disponibles * +10 000 Experts professionnels certifiés * +40 000 prestations réalisées * 4,86/5 de note moyenne * 94% de couverture nationaleCes enseignes nous font confiance : E.Leclerc, Mr. Bricolage, Botanic, Conforama, Monoprix, Casino, La Poste, Carmila…Dealt récompensé par l’écosystème retail français :- Lauréat des Trophées de l’Innovation E.Leclerc 2021, catégorie « Innovation Expérientielle »- Lauréat des Trophées 100% Retailtech LSA 2021, catégorie « Digitalisation du point de vente, expérience client et solution de paiement » - Elu start-up de l’année 2021 lors de l’événement « Connect Lille »Dealt est soutenu par le Groupe La Poste

Mercia Asset Management provides equity and debt to UK businesses with growth ambition. We are your investment partners from scale-up to exit.

Investment focus

Software, Health Care, Biotechnology
Seed, Funding Round, Series A
United Kingdom, United States, Hungary

Portfolio highlights

Kuano — Kuano provides innovative quantum and AI solutions for drug discovery and design. It offers a discovery platform that combines target quantum mapping and AI-led chemistry to enable the faster development of better drug candidates.
MGISS — Independently advising on the smarter use of Geospatial data, technology and the digital transformation of field operations.
Workbuzz — Give your Everyday Heroes a voice with employee surveys. Our flexible and simple survey platform reaches all employees, wherever they are. Book a demo now!

Investment focus

Biotechnology, Health Care, Software
Series A, Seed, Series B
United Kingdom, United States, The Netherlands

Portfolio highlights

natcap — We support the world's leading companies to prioritise, measure and act on nature impacts, dependencies, risks and opportunities.
FluoRok — By employing our patented technology, we can produce fluorochemicals without the production of toxic and highly dangerous hydrofluoric acid
Iota Sciences — Discover automated single-cell handling tools and related services to accelerate your route to breakthrough discoveries in cell biology

Karista is an early-stage venture capital firm created in 2001 investing in Health, Digital, Tech, and NewSpace.

Investment focus

Software, Biotechnology, Health Care
Seed, Series A, Series B
France, United States, Finland

Portfolio highlights

Deemea — Deemea is a collaborative AI platform that connects and provides services for the analysis of medical data for physicians. It uses its expertise in clinical research, data science, and software development to help healthcare professionals.
10Lines — 10Lines is developing autonomous parking lot marking robots and technological solutions to significantly increase productivity in the industry of pavement marking. Our solutions are helping striping businesses do their work much more productively with a smaller environmental footprint.
Brightflow — Brightflow operates as a medical device startup.

BioInnovation Institute is a biotechnology startup that offers entrepreneurs and researchers in life science. Early-stage life science start-ups are supported with up to 10 million DKK in funding, business acceleration, network, labs, and office space. It helps to early-stage start-ups within human health and planetary health. The startup'smission is to use its knowledge, network, funding, and infrastructure to incubate world-class life science and catalyze the commercialization of new solutions through start-ups.BioInnovation Institute was founded in 2018 and is based in Denmark.

Investment focus

Biotechnology, Medical, Health Care
Convertible Note, Pre-Seed, Debt Financing
Denmark, Germany, Switzerland

Portfolio highlights

NorFalk — NorFalk rethinks the way to produce surfactants: the active and stabilizing ingredients in household care and personal care consumer products.
ArcanaBio — ArcanaBio is developing realtime biosurveillance solutions that minimize workplace disruptions and support health & wellness
HHC Medical — HHC Medical is a health tech company developing targeted non-invasive drug delivery devices through electroporation to transfect a large number of cells. It was founded in 2019 and is headquartered in Hillerød, Denmark.

Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, United Kingdom, Switzerland

Portfolio highlights

Enara Bio — Enara Bio is a science-led company targeting the T-cell/cancer cell interface (the “immune synapse”) to develop new targeted cancer immunotherapies designed to treat a broad patient population. Enara Bio focuses on discovering and developing therapeutic cancer vaccines utilizing novel antigens derived from endogenous retroviral (ERV)-relatedDNA sequences.
IonKraft — IonKraft can provide better performance at a lower cost while maintaining recyclability, they also promote material reduction and reuse and are commercializing the technology with funding from the German Federal Ministry for Economic Affairs and Energy (BMWi).
Kivu Bioscience — At Kivu Bioscience, we leverage advanced, next-generation proprietary ADC technologies to deliver more precise and effective cancer treatments.

Epidarex Capital invests in early-stage, high growth life science and health technology companies in under-ventured markets. Its international team is led by Sinclair Dunlop, Kyp Sirinakis and Liz Roper. With offices in the United States and United Kingdom Epidarex Capital’s investors represent a cross-section of leading universities, internationalcorporations, development agencies and financial institutions. Epidarex was created to meet the need for more sector-specific financial backing for young companies, including spin-outs from leading research universities.

Investment focus

Biotechnology, Therapeutics, Health Care
Series A, Seed, Series B
United Kingdom, United States, Germany

Portfolio highlights

Theolytics — Theolytics is a biotechnology company harnessing viruses to combat cancer. A step-change in the oncolytic viral therapy field, our phenotypic screening Platform enables the discovery and development of efficacious, targeted candidates suitable for intravenous delivery and optimised for a chosen patient population. In addition to advancing aninternal Pipeline of programs spanning both solid and liquid tumours, we are establishing select strategic partnerships to expand and accelerate pipeline development.
Curve Therapeutics — Curve has developed an innovative screening platform that is transforming the discovery of first-in-class therapeutics. The platform allows functional screening of diverse, genetically encoded Microcycle™ libraries against a broad range of disease-associated targets that are present in their native conformation inside a mammalian cell. Curve isdeploying this platform to build a pipeline of novel cancer drugs.
Enterprise Therapeutics — Enterprise Therapeutics is a drug discovery company dedicated to the researchand development of novel therapies for the treatment of respiratory diseases.In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlyingmechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.

The Center for Industrial Technological Development (CDTI) is a public corporation under the Ministry of Economy and Competitiveness, which promotes innovation and technological development of Spanish companies. Is the entity which channels requests for funding and support to projects I + D + i of Spanish companies in the national andinternational levels. The CDTI has a staff of more than 300 people formed three quarters of engineers and graduates. Although the bulk of the infrastructure of the CDTI is located in Madrid, the Centre offers Spanish companies a strategic network of offices and representatives abroad (Japan -SBTO (Spain Business and Technology Office) - Belgium -SOST (Spain Office of Science and Technology) and Permanent Secretariat Eureka-, Brazil -FINEP (Financier of Studies and Projects) -, Korea, Chile, Morocco, China, India, Mexico and USA) to support them in their technological activities of type int .

Investment focus

Biotechnology, Health Care, Software
Funding Round, Seed, Grant
Spain, United States, France

Portfolio highlights

Tebrio — At the rate that the world is growing, we’ll only have enough food to feed 50% of our future population by 2050 and introducing novel proteins into the food value chain that are rich in amino acids and use less water and arable land is the only solution forward for mankind and the planet, which is why, in 2014, Adriana Casillas and Sabas de Diegofounded Tebrio, the world’s leading carbon-negative, zero-residue insect biotechnology company, which tackles climate change and the world food crisis by breeding and transforming rich amino acid mealworms into three main co-products: (i) sustainabe premium fish, pet and animal feed (ii) biofertilizer for plant nutrition that acts as a natural pest repellent (iii) chitosan to manufacture biodegradable plastic that disolves in water. Our carbon negative pilot farm produces 500 tons of co-products a year, does not emit greenhouse gases like ammonia or methane, uses 98% less water and 90% less arable land than other animal and plant protein farms, and is the only company in our industry in Spain that has received an ISO9001 certification, which guarantees the quality of our products. Thanks to our current operations, we have secured an undisclosed Series A round, which we are using to develop a EUR 50 million insect farm that will take us from a 500 tn to a 100.000 tns production of co-products a year and will be the largest of its kind in the world. Company Key Metrics: • Tebrio has 8 industrial patents in 150 countries • Tebrio’s operations are carbon negative, zero residue, and we do not emit greenhouse gases like ammonia or methane • With the same amount of natural resources, we are able to produce 500% more protein for fishmeal and animal feed than plant protein and livestock farms • Our protein for fish and animal feed is 90% digestible, 70% protein, high in essential amino acids and unsaturated fat • Tebrio was the first certified producer in the world of mealworm protein for fish and animal feed and biofertilizer for plant nutrition • Our tech powered biofertilizer has 10x more nutrients than other organic fertilizers and thanks to its properties, acts as a natural pest repellent • We are the only Spanish company in our industry with an ISO9001 certification • We are building the world’s largest insect farm, which will produce 100.000 tons of co-products a year for animal feed and plant fertilization • We use big data and 4.0 industries to industrially produce and control the Tenebrio Molitor insect
Zeleros — Leaders in the development of hyperloop technologies, we are your new electrification & automation partner in the mobility sector.
INBRAIN Neuroelectronics — We are scientists, doctors, techies and humanity lovers, with the mission of building neuroelectronic interfaces to cure brain disorders.

Development Bank of Wales is formed in 2001 by the Welsh Assembly Government. Development Bank of Wales is an independent company, providing commercial funding to Welsh SMEs. They invests private and public funds, including EU funds.

Investment focus

Software, Health Care, Biotechnology
Seed, Funding Round, Debt Financing
United Kingdom, Australia, United States

Portfolio highlights

Menna — Be smarter about money and grow faster with Menna. Take control of your business finances today!
Lineat Composites — We introduce a new aligned fibre material format that forms the basis of high-performance sustainable composite materials.
Llusern Scientific — Llusern specialises in rapid and affordable near-patient and POC molecular diagnostics developed to detect bacterial and viral infections.

Zusammen gestalten wir die Unternehmen von morgen.

Investment focus

Biotechnology, Health Care, Medical
Series A, Funding Round, Series B
Germany, France, Austria

Portfolio highlights

Inbolt — InBolt has developed the world’s smallest and most efficient 3D camera tracking system. Their first product is a hardware module / device that an operator can plug onto all manual tools such as a drill, a screwdriver or a torque wrench. Once on the tool, it guides the operator, validates the completion of a task in real time and registers allthe completion parameters.
SciRhom — SciRhom GmbH is a biotech company that translates science into the preclinical and early clinical development of novel biopharmaceuticals for the treatment of life-threatening autoimmune diseases. Based on longstanding academic research and a well-established network of experts, SciRhom was founded in 2016 through a collaboration between academicand industry scientists with profound experience in antibody development.
Innatera — Innatera is a Dutch nanotech company and an offspring of the Delft University of Technology in the Netherlands.

Since 1998, AURIGA PARTNERS, an independent Venture Capital firm, has been managing several early stage funds specializing in Information Technology and Life Sciences.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Funding Round
France, United States, Switzerland

Portfolio highlights

Patrowl — Identify and harden your External Security Posture with the leader. Let us manage time-consuming tasks and focus on remediation
Exeliom — Exeliom is a clinical-stage biopharmaceutical company tackling the use of commensal bacteria as drugs. Their mission is to harness the therapeutic potential of gut microbiota to enable people to lead longer and healthier lives. They are committed to developing the next generation of probiotics: innovative microbial therapies.Exeliom develops anew class of medicines called Live Biotherapeutics based on their growing understanding of the central role of the microbiota in the immune system.The company was founded in 2016 and is headquartered in Dijon, France.
Vade Secure — Vade is a global leader in predictive email defense, protecting 1 billion inboxes worldwide. AI-based email security for Microsoft 365.

Brilliant Ideas. Brilliant People. Brilliant Minds.

Investment focus

Biotechnology, Health Care, Software
Seed, Funding Round, Convertible Note
United Kingdom, United States, Canada

Portfolio highlights

Ikarovec — Ikarovec is developing novel gene therapies to treat major ophthalmic indications.
Antiverse — Designing biologics for 100 challenging targets
Wittaya Aqua — A better approach to aquaculture management

Established in 1992. Archangels is the oldest continuously operating business angel syndicate in the World. Investing in IP-rich tech & life sciences companies in Scotland, UK.

Investment focus

Software, Biotechnology, Health Care
Funding Round, Seed, Series A
United Kingdom, United States

Portfolio highlights

Bio-Images Drug Delivery — BDD Pharma combine drug delivery expertise and clinical capabilities to accelerate product development pipelines, enable life cycle management and new innovative pharmaceutical products. Rapid parallel clinical testing with SWIFT significantly reduces time from product concept to clinical success.
1inhaler — 1inhaler operates as a developer of drug delivery device.
iGii — Integrated Graphene enable better products with a revolutionary design for manufacture process producing the world's highest quality pure 3D Graphene Foam, Gii.

Omnes VC is the Venture Capital arm of Omnes Capital, a leading private equity firm dedicated to energy transition and innovation with €4.8 billion in assets under management and a 20 year + experience in: venture capital, buyout & growth capital, private debt, renewable energy, co-investment, secondary funds of funds. Omnes Capital is fullyindependent.With 65 business sales including 14 IPOs carried out in 16 years, Omnes VC is one of the key players in France in financing innovative SMEs with expertise in both Technology and Healthcare sectors. Omnes VC has supported 120 companies and has invested more than €500M in businesses such as Scality, Novaled, BioVex, arGEN-X, Pixium, Blablacar.

Investment focus

Biotechnology, Software, Health Care
Series A, Funding Round, Series B
France, Germany, United States

Portfolio highlights

Qantev — Qantev is the leading AI claims platform for health & life insurance, enabling insurers to automate claims operations, reduce leakage, improve loss ratios, enhance data quality, and elevate customer experience.
Carbyon — Carbyon is a Netherlands-based company that develops direct air capture (DAC) technologies. The company's fuels help to replace fossil hydrocarbons with electrical batteries or hydrogen (H2), alternative energy carriers that are used to store renewable electricity and make major changes to transportation facilities, energy grids, and gastransportation networks, filters CO2 from the air and supply it in a purified form to make kerosene for aircraft, enabling existing fossil industry to re-use and repurpose these storage and transport facilities for renewable hydrocarbons.
The Exploration Company — For Space & Non-Space Industries.

Idinvest Partners is a pan-European private equity manager focused on the low and middle-market segments. With over 6 billion euros under management, the company has developed several complementary areas of expertise, including equity investments in buyout deals focusing on both mid-size as well as young innovative European companies; primaryinvestments in European private equity funds focusing primarily on the middle market segment; secondary investments; mezzanine investments in Europe; and private equity consulting.Idinvest Partners’ recent success stories include Criteo, Clear2Pay, Meetic, Prosensa, Converteam, Kwik Fit, Lastminute.com, Dailymotion, Deezer, Talend, Synthesio, Menlook, Vestiaire Collective, Pretty Simple, Curse.com, Withings, Kantox, Secret Escapes, Happn, Peakon, Dayuse, Botify, Financefox, Azalead and many more.

Investment focus

Biotechnology, Health Care, Software
Series B, Series A, Funding Round
France, United States, Spain

Portfolio highlights

Corti — Corti offers a digital assistant, augmenting medics in improving patient outcomes and internal performance.
Coave Therapeutics — Coave Therapeutics is active in the field of gene therapies in rare ocular and CNS (Central Nervous System) diseases.
Stilla Technologies — Stilla Technologies is taking digital PCR to a whole new level with a unique 6-color target detection capability

Newable: Helping over 20,000 businesses thrive annually with tailored financial products, advice, and flexible workspace solution

Investment focus

Software, Health Care, Biotechnology
Seed, Funding Round, Series A
United Kingdom, United States

Portfolio highlights

Delta g — Delta g Limited is a quantum technology and gravity gradiometry company. A spin-out from the University of Birmingham our technology has applications in industries as varied as civil engineering, infrastructure, defence, rail, navigation and resource exploration. Experts from science, engineering an
Weldfast — Weldfast is a manufacturer and supplier of welding consumables, abrasives, chemicals, premium gas equipment, and safety products.
EarSwitch — Empowering new ways to control and connect with the world through in-ear biometric switch and sensor technology

AlbionVC supports visionary founders with long-term capital and scale-up expertise. Founded in 1996, today we are partners to UK early-stage B2B software and healthcare companies. AlbionVC manages c. $1 billion of venture funds, currently invested in over 50 companies. AlbionVC is the technology investment arm of Albion Capital Group LLP, which isauthorised and regulated by the Financial Conduct Authority.

Investment focus

Software, Health Care, Information Technology
Series A, Funding Round, Seed
United Kingdom, United States, France

Portfolio highlights

Diffblue — Diffblue Cover uses next generation autonomous AI to automate unit testing so that Java development teams can build better applications faster
tem. — In a few simple steps we can manage your renewable energy needs forever.
Infact Systems — Infact Systems is a company that focuses on bringing affordability and credit information into the 21st century. They facilitate the sharing of real-time, contextual data, primarily in the banking industry. Their mission is to increase responsible financial behavior by providing real-time data for modern credit. They offer integration andcustomization services for HPZone, particularly in terms of connecting with external laboratory systems. Infact Systems also provides services to help women take control of their finances.

Focused on seeding early stage biotech therapeutics and related AI opportunities. The fund will invest in companies qualifying under EIS and covering novel...

Investment focus

Biotechnology, Health Care, Pharmaceutical
Seed, Series A, Pre-Seed
United Kingdom, Hungary

Portfolio highlights

Healx — At Healx we use AI drug discovery to develop new treatments for rare diseases. We bring treatments from prediction to patient.
ViaNautis — Precision Solutions
Pencil Biosciences — Next Generation Genome Editing Tool

Deepbridge is a different kind of investment manager. They work closely with financial advisers and investors to design innovative products, ranging from investment in technology growth companies to asset-backed renewable energy projects. They also partner with innovative and committed management teams to help UK based companies realise theirpotential and become successful leading-edge businesses.

Investment focus

Health Care, Biotechnology, Medical
Seed, Funding Round, Series A
United Kingdom, Australia, Singapore

Portfolio highlights

AI-Sight — AI-Sight is a startup that is developing an AI diabetic retinal screening system to deliver WHO-recommended diabetic eye screening services.
Microplate Dx — Safeguarding against the spread of antimicrobial resistance worldwide.
GenoMe Diagnostics — GenoME Diagnostics - We are developing a blood test for an earlier and more accurate diagnosis of ovarian cancer.GenoME Diagnostics .

Criteria Venture Tech is the tech VC fund of CriteriaCaixa which invests in B2B SaaS and DeepTech companies in early and growth stages (Pre-Seed to Series C) managing more than €300M of AUM.

Investment focus

Software, Biotechnology, E-Commerce
Seed, Funding Round, Series A
Spain, United States, United Kingdom

Portfolio highlights

Enline — Technology for Power Systems, TRANSMISSION AND DISTRIBUTION SYSTEM OPERATORS, INDUSTRY AND MINING, ENGINEERING & CONSTRUCTION, INSURANCE AND CONSULTANCY, UTILITIES & POWER GENERATION, ENLINE MONITORING SYSTEM, ENLINE DYNAMIC LINE RATING, ENLINE FAULT LOCATION, ENLINE POWER OPTIMIZATION .
Medlumics — Medlumics is a medical device start-up born in 2009 from a compromise with improving human living standards by means of technology.
KIT-AR — Reduce time and costs spent fixing errors on your manufacturing shopfloor with quality assurance and augmented reality- Click in to find how!

Elaia is French venture capital firm focused on European digital and deep tech startups, from early stage to growth developpement. We back tech disruptors.

Investment focus

Software, Information Technology, Artificial Intelligence
Seed, Series A, Series B
France, United States, Spain

Portfolio highlights

Qantev — Qantev is the leading AI claims platform for health & life insurance, enabling insurers to automate claims operations, reduce leakage, improve loss ratios, enhance data quality, and elevate customer experience.
SURGAR — SURGAR provides a plug-and-play augmented reality software suite for computer-aided laparoscopic surgery.
Dunia Innovation — Catalysing the energy transition.

The GM&C Life Sciences Fund is a seed and early stage venture capital fund targeting life sciences businesses located in the Greater Manchester and Cheshire & Warrington region. The Fund is managed by Catapult Venture Managers ("Catapult Ventures").The Fund is based at Alderley Park, which is well recognised as a site ofnational importance, being the largest life sciences campus of its kind in the UK with more than 500,000 sq. ft. of top-end laboratory and related space and facilities. Until recently, the Park was the R&D headquarters for AstraZeneca.Since 2002, Catapult Ventures has backed a significant number of companies across a broad range of life sciences, including therapeutics (such as Abzena and Oxford BioTherapeutics), medical devices (such as Monica Healthcare and Probe Scientific), contract research organisations (such as R5 Pharmaceuticals and FDAS), diagnostics developers (such as Lumora and Biofortuna), as well as developers of technology used in healthcare applications (such as Oxford Cryosystems and Accutronics). The Fund is the result of a collaboration between Cheshire and Warrington Enterprise Partnership, Greater Manchester Combined Authority, Cheshire East Council, and Manchester Science Partnerships.

Investment focus

Health Care, Biotechnology, Medical
Seed, Funding Round, Series A
United Kingdom, Italy, Germany

Portfolio highlights

ScubaTx — ScubaTx is a breakthrough organ preservation device organ transplant. The ScubaTx device will leverage world-leading expertise in software design to commercialise a proven but unexploited organ preservation technique, Persufflation. ScubaTx will offer healthcare providers significant net savings, an
Flynotes — Flynotes is a digital software platform helping dentists deliver personalised patient care
QV Bioelectronics — Manchester-based start-up QV Bioelectronics is developing innovative electrotherapy devices for the treatment of certain types of brain tumours.

Noshaq offers financial services to help businesses develop.

Investment focus

Biotechnology, Health Care, Medical
Seed, Series A, Funding Round
Belgium, France, Germany

Portfolio highlights

Veoware — More coverage, shorter revisit time. Increasing target collection frequency through modular next-gen actuator technology.
Get Your Way — Discover the future of assisted reality with Get Your Way's aRdent smart glasses. Perfect for SMEs looking for innovative solutions to improve their business
Brenus Pharma — Brenus Pharma is an allogeneic platform to generate immune therapy ambitioning to harness patient immune system & prevent cancer resistance over treatment.

HealthCap, a life science investor and company creator. Our motivation is to find innovative ideas and invest that could impact healthcare and society.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Funding Round
United States, Sweden, France

Portfolio highlights

Kivu Bioscience — At Kivu Bioscience, we leverage advanced, next-generation proprietary ADC technologies to deliver more precise and effective cancer treatments.
Rampart Bioscience — Rampart Bioscience develops gene medicines to provide long-lasting treatments for a wide range of diseases. It also offers proprietary development and delivery platforms, which together, create optimized therapeutics in a revocable, non-viral format. It also assists patients with genetically driven diseases by integrating capabilities from avariety of key scientific disciplines including gene delivery, protein sciences, and clinical translation.
SynOx Therapeutics — SynOx Therapeutics is a biotechnology research company that focused on developing the treatment of diffuse tenosynovial giant cell tumors. SynOx Therapeutics raises EUR 37m to develop emactuzumab to improve the lives of patients with tenosynovial giant cell tumors November 16, 2020. It was founded in 2020 and is located in Dublin City, Ireland.

IP Group's core business is the creation of value for its shareholders and partners through the commercialisation of intellectual property originating from research intensive institutions. Their strength lies in managing this process from finding suitable intellectual property to commercialise to either helping develop businesses and createvalue out of them, or identifying and establishing appropriate commercial partnerships to do so. IP Group's extensive expertise in this area combined with its inside knowledge of both industry and finance have enabled the group to create a formidable track record of consistently delivering excellent results for their companies, for their partners and for their shareholders.

Investment focus

Health Care, Biotechnology, Therapeutics
Seed, Series A, Series B
United Kingdom, United States, Australia

Portfolio highlights

Diffblue — Diffblue Cover uses next generation autonomous AI to automate unit testing so that Java development teams can build better applications faster
Microbiotica — Microbiotica is a developer of human microbiome therapeutics intended to discover and develop live bacterial therapeutics and biomarkers. The company's therapeutics identify gut bacteria linked to phenotype with unprecedented precision, enabling researchers to phenotype before testing of candidate bacteria in advanced human in vitro and invivo models.
MISSION Therapeutics — Deubiquitylating enzymes: multiple drug opportunities across therapeutic areas

Impacting the future of medicine.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Series C
United States, United Kingdom, The Netherlands

Portfolio highlights

Solasta Bio — Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection.
SynOx Therapeutics — SynOx Therapeutics is a biotechnology research company that focused on developing the treatment of diffuse tenosynovial giant cell tumors. SynOx Therapeutics raises EUR 37m to develop emactuzumab to improve the lives of patients with tenosynovial giant cell tumors November 16, 2020. It was founded in 2020 and is located in Dublin City, Ireland.
Navigator Medicines — Leading the advancement of biologics for targeted immune regulation & restoration.

The Cambridge Angels are a group of high-net worth investors who have proven experience as successful entrepreneurs in internet, software, technology and bio-technology. Members invest in and mentor high quality start-up and early-stage companies in these sectors in the Cambridge (UK) area and throughout the UK.Typical funding requirements thatthe Cambridge Angels meet are in the range of £50,000 to £500,000 - although it is worth noting that several of their portfolio companies have received more than £1m in funding from their Members over several funding rounds.Their Members have been responsible for a large number of the “Cambridge Phenomenon” success stories over recent years. Therefore, in addition to providing funding for early-stage companies, the Cambridge Angels also offer start-ups the considerable benefit of a wide range of expertise, contacts and directly relevant experience in establishing and growing entrepreneurial businesses successfully.

Investment focus

Software, Health Care, Biotechnology
Seed, Funding Round, Series A
United Kingdom, United States, Estonia

Portfolio highlights

xWatts — xWatts is an intelligent energy management software that reduces energy costs and emissions in commercial buildings.
Qureight — Pioneering data curation to solve complex diseases
Monument Therapeutics — Monument Therapeutics is a biotechnology company intended to develop drugs to treat serious diseases of the central nervous system.

We invest venture capital in to globally ambitious companies which have the potential to deliver a significant return to our investors

Investment focus

Health Care, Biotechnology, Manufacturing
Seed, Funding Round, Series A
United Kingdom, United States

Portfolio highlights

Chromacity — Chromacity manufacture the next generation of ultrafast lasers. Discover our fixed wavelength femtosecond lasers and picosecond OPOs.
Biotangents — Biotangents develops veterinary diagnostic tests to detect infectious diseases in livestock (bovine viral diarrhoea (BVD), mastitis, bovine respiratory disease (BRD), brucellosis) using our highly adaptable molecular diagnostic technology, Moduleic Sensing.
Sofant Technologies — Sofant is developing a low cost RF MEMS technology that solves power consumption and heat problems in high frequency phased array antenna systems.

We provide venture capital investment for the people, ideas and industries that will change the world. Learn about what we do and the kind of founders we back.

Investment focus

Software, Health Care, Information Technology
Series A, Seed, Series B
United Kingdom, United States, Germany

Portfolio highlights

Cogna — Cogna offers an AI-powered SaaS platform that streamlines the integration of data across several business domains.
Cambri — Cambri is concept testing software that helps global brands accelerate their innovation process.
Forefront RF — Forefront RF tunable duplexer aims to expand the accessibility and global market reach of all mobile devices by simplifying RFFE design.

Leading #lifesciences #venturecapital firm financing highly #innovative #biotechnology companies #worlwide.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
Spain, United States, Switzerland

Portfolio highlights

ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
Memo Therapeutics — Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis.Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’simmune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations.
Engrail Therapeutics — Engrail delivers transformational therapies that improve the lives of patients with devastating neurologic, neuropsychiatric, and neurodevelopmental disorders.

Syncona is a FTSE250 company focused on founding, building and funding healthcare companies to deliver transformational treatments to patients in areas of high unmet need.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Seed
United Kingdom, United States, Switzerland

Portfolio highlights

iOnctura — Our mission is to develop high impact, low disruption therapies that extend healthspan. We do this by disrupting the dynamic interplay at the heart of the
Purespring Therapeutics — Purespring Therapeutics is an AAV gene therapy company focused on the kidney globally.
Resolution Therapeutics — Resolution Therapeutics is a biopharmaceutical company developing macrophage cell therapy to treat chronic diseases.

Northstar Ventures invests venture capital in early and later stage, high growth companies tackling global challenges, focusing on climate tech and healthy ageing.

Investment focus

Software, E-Commerce, SaaS
Seed, Funding Round, Series A
United Kingdom, United States, Indonesia

Portfolio highlights

Lightox — Lightox has developed a unique range of molecular tools for use in imaging, therapeutics and assay development. These unique probes are smaller than any other commercially available fluorescent product. They offer the option of using our technologies as freely-moving probes that readily incorporate into cells or with a range of flexible linkers togive specificity to your unique applications and research needs.
DayaTani — DayaTani supplies farmers with comprehensive services to increase their productivity.
Circadacare — Circadacare helps elderly people and people with dementia live independently for longer with an integrated circadian lighting and home health monitoring system.

Wellcome Trust is a medical research charity that funds research that aims to protect and improving human and animal health. It focuses on the fields of public engagement, investments, innovation, humanities, and social science. It was founded in 1936 and headquartered in London, England.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Grant, Series C, Funding Round
United States, United Kingdom, Germany

Portfolio highlights

Vaxxas — Vaxxas develops and commercializes needle-free vaccine delivery system. Vaxxas was incorporated in 2011 and is based in Brisbane, Australia.
DataDotOrg — data.org brings together philanthropy, technology, academia, and social impact organizations to build the field of data science for social impact.
Feinstein Institute for Medical Research — Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes ofbehavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

Investors by industry

Artificial intelligence